Literature DB >> 15514230

Research and development of new vaccines against infectious diseases.

Marie Paule Kieny1, Jean-Louis Excler, Marc Girard.   

Abstract

Infectious diseases are responsible for approximately 25% of global mortality, especially in children aged younger than 5 years. Much of the burden of infectious diseases could be alleviated if appropriate mechanisms could be put in place to ensure access for all children to basic vaccines, regardless of geographical location or economic status. In addition, new safe and effective vaccines should be developed for a variety of infections against which no effective preventive intervention measure is either available or practical. The public, private, and philanthropic sectors need to join forces to ensure that these new or improved vaccines are fully developed and become accessible to the populations in need as quickly as possible.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15514230      PMCID: PMC1448562          DOI: 10.2105/ajph.94.11.1931

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  6 in total

1.  The future of vaccines: an industrial perspective.

Authors:  M Gréco
Journal:  Vaccine       Date:  2001-10-15       Impact factor: 3.641

2.  Public-private partnerships for health: their main targets, their diversity, and their future directions.

Authors:  R Widdus
Journal:  Bull World Health Organ       Date:  2001-10-24       Impact factor: 9.408

3.  How the research-based industry approaches vaccine development and establishes priorities.

Authors:  F E André
Journal:  Dev Biol (Basel)       Date:  2002

4.  Medicine. The need for a global HIV vaccine enterprise.

Authors:  Richard D Klausner; Anthony S Fauci; Lawrence Corey; Gary J Nabel; Helene Gayle; Seth Berkley; Barton F Haynes; David Baltimore; Chris Collins; R Gordon Douglas; Jose Esparza; Donald P Francis; N K Ganguly; Julie Louise Gerberding; Margaret I Johnston; Michel D Kazatchkine; Andrew J McMichael; Malegapuru W Makgoba; Giuseppe Pantaleo; Peter Piot; Yiming Shao; Edmund Tramont; Harold Varmus; Judith N Wasserheit
Journal:  Science       Date:  2003-06-27       Impact factor: 47.728

5.  Vaccine R&D success rates and development times.

Authors:  M M Struck
Journal:  Nat Biotechnol       Date:  1996-05       Impact factor: 54.908

6.  First 5 years of measles elimination in southern Africa: 1996-2000.

Authors:  Robin Biellik; Simon Madema; Anne Taole; Agnes Kutsulukuta; Ernestina Allies; Rudi Eggers; Ntombenhle Ngcobo; Mavis Nxumalo; Adelaide Shearley; Egleah Mabuzane; Erica Kufa; Jean-Marie Okwo-Bele
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

  6 in total
  3 in total

1.  Do we need new antibiotics? The search for new targets and new compounds.

Authors:  Jaroslav Spížek; Jitka Novotná; Tomáš Rezanka; Arnold L Demain
Journal:  J Ind Microbiol Biotechnol       Date:  2010-11-18       Impact factor: 3.346

2.  Aedes aegypti NeSt1 Protein Enhances Zika Virus Pathogenesis by Activating Neutrophils.

Authors:  Andrew K Hastings; Ryuta Uraki; Hallie Gaitsch; Khushwant Dhaliwal; Sydney Stanley; Hannah Sproch; Eric Williamson; Tyler MacNeil; Alejandro Marin-Lopez; Jesse Hwang; Yuchen Wang; Jonathan R Grover; Erol Fikrig
Journal:  J Virol       Date:  2019-06-14       Impact factor: 5.103

Review 3.  The expanding role of mass spectrometry in the field of vaccine development.

Authors:  Vaneet Kumar Sharma; Ity Sharma; James Glick
Journal:  Mass Spectrom Rev       Date:  2018-05-31       Impact factor: 10.946

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.